echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > AstraZeneca Selumetinib and Tagrisso were promoted by the European Union...

    AstraZeneca Selumetinib and Tagrisso were promoted by the European Union...

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompileKe Ke

    On April 26, AstraZeneca announced that its drug selumetinib, developed in cooperation with Merck & Co.


    On the same day, AstraZeneca also announced that Tagrisso (osimertinib) has also been recommended for marketing in the European Union for the adjuvant treatment of early (IB, II and IIIA) epidermal growth factor receptor mutations (EGFRm) non-small cell lung cancer (NSCLC) adults Patients, these patients still have treatment intentions after the tumor is completely removed.


    Selumetinib

    Selumetinib

    AstraZeneca and Merck introduced that the European Medicines Agency's (EMA) Committee for Human Medicines (CHMP) published the results of the Phase II clinical trial SPRINT Stratum 1 sponsored by the National Cancer Institute (NCI) Cancer Treatment Evaluation Project (CTEP) Positive opinions.


    The Phase 1/2 clinical trial SPRINT Stratum 1 aims to evaluate the objective response rate and the impact of patient reports and functional outcome analysis on children with NF1-related inoperable PNs treated with selumetinib monotherapy.


    Selumetinib is an inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2).


    Selumetinib was approved in the United States in April 2020 for the treatment of pediatric patients with NF1 and symptomatic, inoperable PN.


    Tagrisso

    Tagrisso

    According to AstraZeneca, CHMP gave a positive opinion on the results of the Phase III clinical trial ADAURA.


    ADAURA is a randomized, double-blind, global, placebo-controlled phase three clinical trial used for adjuvant therapy in 682 patients with stage IB, II, and IIIA EGFRm NSCLC.


    Tagrisso (osimertinib) is a third-generation irreversible EGFR-TKI with clinical activity against central nervous system metastasis.


    Currently, Tagrisso's Phase III trial of locally advanced unresectable group (LAURA), neoadjuvant resectable group (Neoadura) and combination chemotherapy group (FLAURA2) are still ongoing.


    Reference source:

    Reference source:

    1.


    1.


    2.
    Tagrisso recommended for approval in the EU by CHMP for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.